André Dallmann1, Ibrahim Ince2, Juri Solodenko3, Michaela Meyer4, Stefan Willmann4, Thomas Eissing5, Georg Hempel1. 1. Department of Pharmaceutical and Medical Chemistry-Clinical Pharmacy, Westfälische Wilhelm-University Münster, 48149, Münster, Germany. 2. Bayer AG, Drug Discovery, Pharmaceuticals, Systems Pharmacology & Medicine I, Kaiser-Wilhelm-Allee, 51373, Leverkusen, Germany. ibrahim.ince@bayer.com. 3. Bayer AG, ET-TD-ET Systems Pharmacology ONC, 51368, Leverkusen, Germany. 4. Bayer AG, DD-CS Clinical Pharmacometrics, 42113, Wuppertal, Germany. 5. Bayer AG, Drug Discovery, Pharmaceuticals, Systems Pharmacology & Medicine I, Kaiser-Wilhelm-Allee, 51373, Leverkusen, Germany.
Abstract
BACKGROUND: Since pregnant women are considerably underrepresented in clinical trials, information on optimal dosing in pregnancy is widely lacking. Physiologically based pharmacokinetic (PBPK) modeling may provide a method for predicting pharmacokinetic changes in pregnancy to guide subsequent in vivo pharmacokinetic trials in pregnant women, minimizing associated risks. OBJECTIVES: The goal of this study was to build and verify a population PBPK model that predicts the maternal pharmacokinetics of three predominantly renally cleared drugs (namely cefazolin, cefuroxime, and cefradine) at different stages of pregnancy. It was further evaluated whether the fraction unbound (f u) could be estimated in pregnant women using a proposed scaling approach. METHODS: Based on a recent literature review on anatomical and physiological changes during pregnancy, a pregnancy population PBPK model was built using the software PK-Sim®/MoBi®. This model comprised 27 compartments, including nine pregnancy-specific compartments. The PBPK model was verified by comparing the predicted maternal pharmacokinetics of cefazolin, cefuroxime, and cefradine with observed in vivo data taken from the literature. The proposed scaling approach for estimating the f u in pregnancy was evaluated by comparing the predicted f u with experimentally observed f u values of 32 drugs taken from the literature. RESULTS: The pregnancy population PBPK model successfully predicted the pharmacokinetics of cefazolin, cefuroxime, and cefradine at all tested stages of pregnancy. All predicted plasma concentrations fell within a 2-fold error range and 85% of the predicted concentrations within a 1.25-fold error range. The f u in pregnancy could be adequately predicted using the proposed scaling approach, although a slight underestimation was evident in case of drugs bound to α1-acidic glycoprotein. CONCLUSION: Pregnancy population PBPK models can provide a valuable tool to predict a priori the pharmacokinetics of predominantly renally cleared drugs in pregnant women. These models can ultimately support informed decision making regarding optimal dosing regimens in this vulnerable special population.
BACKGROUND: Since pregnant women are considerably underrepresented in clinical trials, information on optimal dosing in pregnancy is widely lacking. Physiologically based pharmacokinetic (PBPK) modeling may provide a method for predicting pharmacokinetic changes in pregnancy to guide subsequent in vivo pharmacokinetic trials in pregnant women, minimizing associated risks. OBJECTIVES: The goal of this study was to build and verify a population PBPK model that predicts the maternal pharmacokinetics of three predominantly renally cleared drugs (namely cefazolin, cefuroxime, and cefradine) at different stages of pregnancy. It was further evaluated whether the fraction unbound (f u) could be estimated in pregnant women using a proposed scaling approach. METHODS: Based on a recent literature review on anatomical and physiological changes during pregnancy, a pregnancy population PBPK model was built using the software PK-Sim®/MoBi®. This model comprised 27 compartments, including nine pregnancy-specific compartments. The PBPK model was verified by comparing the predicted maternal pharmacokinetics of cefazolin, cefuroxime, and cefradine with observed in vivo data taken from the literature. The proposed scaling approach for estimating the f u in pregnancy was evaluated by comparing the predicted f u with experimentally observed f u values of 32 drugs taken from the literature. RESULTS: The pregnancy population PBPK model successfully predicted the pharmacokinetics of cefazolin, cefuroxime, and cefradine at all tested stages of pregnancy. All predicted plasma concentrations fell within a 2-fold error range and 85% of the predicted concentrations within a 1.25-fold error range. The f u in pregnancy could be adequately predicted using the proposed scaling approach, although a slight underestimation was evident in case of drugs bound to α1-acidic glycoprotein. CONCLUSION: Pregnancy population PBPK models can provide a valuable tool to predict a priori the pharmacokinetics of predominantly renally cleared drugs in pregnant women. These models can ultimately support informed decision making regarding optimal dosing regimens in this vulnerable special population.
Authors: H M Crauwels; T N Kakuda; B Ryan; C Zorrilla; O O Osiyemi; S Yasin; K Brown; P Verboven; V Hillewaert; B Baugh Journal: HIV Med Date: 2016-05-17 Impact factor: 3.180
Authors: Thomas Eissing; Lars Kuepfer; Corina Becker; Michael Block; Katrin Coboeken; Thomas Gaub; Linus Goerlitz; Juergen Jaeger; Roland Loosen; Bernd Ludewig; Michaela Meyer; Christoph Niederalt; Michael Sevestre; Hans-Ulrich Siegmund; Juri Solodenko; Kirstin Thelen; Ulrich Telle; Wolfgang Weiss; Thomas Wendl; Stefan Willmann; Joerg Lippert Journal: Front Physiol Date: 2011-02-24 Impact factor: 4.566
Authors: Xiaomei I Liu; Jeremiah D Momper; Natella Rakhmanina; John N van den Anker; Dionna J Green; Gilbert J Burckart; Brookie M Best; Mark Mirochnick; Edmund V Capparelli; André Dallmann Journal: J Clin Pharmacol Date: 2019-09-06 Impact factor: 3.126
Authors: Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann Journal: Clin Pharmacokinet Date: 2020-11 Impact factor: 6.447
Authors: Hongfei Zhang; Hari V Kalluri; Jaime R Bastian; Huijun Chen; Ali Alshabi; Steve N Caritis; Raman Venkataramanan Journal: Br J Clin Pharmacol Date: 2018-06-21 Impact factor: 4.335
Authors: Rebekka Fendt; Ute Hofmann; Annika R P Schneider; Elke Schaeffeler; Rolf Burghaus; Ali Yilmaz; Lars Mathias Blank; Reinhold Kerb; Jörg Lippert; Jan-Frederik Schlender; Matthias Schwab; Lars Kuepfer Journal: CPT Pharmacometrics Syst Pharmacol Date: 2021-06-26
Authors: Samit Ganguly; Andrea N Edginton; Jacqueline G Gerhart; Michael Cohen-Wolkowiez; Rachel G Greenberg; Daniel Gonzalez Journal: Clin Pharmacokinet Date: 2021-06-22 Impact factor: 5.577